260 related articles for article (PubMed ID: 26675289)
41. A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.
Wang L; Šuštić T; Leite de Oliveira R; Lieftink C; Halonen P; van de Ven M; Beijersbergen RL; van den Heuvel MM; Bernards R; van der Heijden MS
Eur Urol; 2017 Jun; 71(6):858-862. PubMed ID: 28108151
[TBL] [Abstract][Full Text] [Related]
42. Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models.
Grünewald S; Politz O; Bender S; Héroult M; Lustig K; Thuss U; Kneip C; Kopitz C; Zopf D; Collin MP; Boemer U; Ince S; Ellinghaus P; Mumberg D; Hess-Stumpp H; Ziegelbauer K
Int J Cancer; 2019 Sep; 145(5):1346-1357. PubMed ID: 30807645
[TBL] [Abstract][Full Text] [Related]
43. Targeting Fibroblast Growth Factor Receptor (FGFR) and Phosphoinositide 3-kinase (PI3K) Signaling Pathways in Medulloblastoma Cell Lines.
Holzhauser S; Lukoseviciute M; Andonova T; Ursu RG; Dalianis T; Wickström M; Kostopoulou ON
Anticancer Res; 2020 Jan; 40(1):53-66. PubMed ID: 31892552
[TBL] [Abstract][Full Text] [Related]
44. Icotinib hydrochloride enhances the effect of radiotherapy by affecting DNA repair in colorectal cancer cells.
Ma H; Bi J; Liu T; Ke Y; Zhang S; Zhang T
Oncol Rep; 2015 Mar; 33(3):1161-70. PubMed ID: 25572529
[TBL] [Abstract][Full Text] [Related]
45. E7080 (lenvatinib), a multi-targeted tyrosine kinase inhibitor, demonstrates antitumor activities against colorectal cancer xenografts.
Wiegering A; Korb D; Thalheimer A; Kämmerer U; Allmanritter J; Matthes N; Linnebacher M; Schlegel N; Klein I; Ergün S; Germer CT; Otto C
Neoplasia; 2014 Nov; 16(11):972-81. PubMed ID: 25425971
[TBL] [Abstract][Full Text] [Related]
46. Antitumor Effects and Mechanisms of AZD4547 on FGFR2-Deregulated Endometrial Cancer Cells.
Kwak Y; Cho H; Hur W; Sim T
Mol Cancer Ther; 2015 Oct; 14(10):2292-302. PubMed ID: 26294741
[TBL] [Abstract][Full Text] [Related]
47. High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial.
Pearson A; Smyth E; Babina IS; Herrera-Abreu MT; Tarazona N; Peckitt C; Kilgour E; Smith NR; Geh C; Rooney C; Cutts R; Campbell J; Ning J; Fenwick K; Swain A; Brown G; Chua S; Thomas A; Johnston SRD; Ajaz M; Sumpter K; Gillbanks A; Watkins D; Chau I; Popat S; Cunningham D; Turner NC
Cancer Discov; 2016 Aug; 6(8):838-851. PubMed ID: 27179038
[TBL] [Abstract][Full Text] [Related]
48. Crizotinib Fails to Enhance the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Xenografts.
Baschnagel AM; Galoforo S; Thibodeau BJ; Ahmed S; Nirmal S; Akervall J; Wilson GD
Anticancer Res; 2015 Nov; 35(11):5973-82. PubMed ID: 26504020
[TBL] [Abstract][Full Text] [Related]
49. [Ponatinib inhibits growth of patient-derived xenograft of cholangiocarcinoma expressing FGFR2-CCDC6 fusion protein in nude mice].
Wu T; Jiang X; Xu B; Wang Y
Nan Fang Yi Ke Da Xue Xue Bao; 2020 Oct; 40(10):1448-1456. PubMed ID: 33118510
[TBL] [Abstract][Full Text] [Related]
50. FGFR inhibitor, AZD4547, impedes the stemness of mammary epithelial cells in the premalignant tissues of MMTV-ErbB2 transgenic mice.
Zhao Q; Parris AB; Howard EW; Zhao M; Ma Z; Guo Z; Xing Y; Yang X
Sci Rep; 2017 Sep; 7(1):11306. PubMed ID: 28900173
[TBL] [Abstract][Full Text] [Related]
51. Biological evaluation of 2-arylidene-4, 7-dimethyl indan-1-one (FXY-1): a novel Akt inhibitor with potent activity in lung cancer.
Rajagopalan P; Alahmari KA; Elbessoumy AA; Balasubramaniam M; Suresh R; Shariff ME; Chandramoorthy HC
Cancer Chemother Pharmacol; 2016 Feb; 77(2):393-404. PubMed ID: 26781309
[TBL] [Abstract][Full Text] [Related]
52. Bioactive Peptides Sensitize Cells to Anticancer Effects of Oxaliplatin in Human Colorectal Cancer Xenografts in Nude Mice.
Li X; Xia L; Ouyang X; Suyila Q; Su L; Su X
Protein Pept Lett; 2019; 26(7):512-522. PubMed ID: 30950338
[TBL] [Abstract][Full Text] [Related]
53. Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer.
Chang J; Wang S; Zhang Z; Liu X; Wu Z; Geng R; Ge X; Dai C; Liu R; Zhang Q; Li W; Li J
Oncotarget; 2015 Feb; 6(4):2009-22. PubMed ID: 25576915
[TBL] [Abstract][Full Text] [Related]
54. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
André F; Bachelot T; Campone M; Dalenc F; Perez-Garcia JM; Hurvitz SA; Turner N; Rugo H; Smith JW; Deudon S; Shi M; Zhang Y; Kay A; Porta DG; Yovine A; Baselga J
Clin Cancer Res; 2013 Jul; 19(13):3693-702. PubMed ID: 23658459
[TBL] [Abstract][Full Text] [Related]
55. FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro.
Künstlinger H; Fassunke J; Schildhaus HU; Brors B; Heydt C; Ihle MA; Mechtersheimer G; Wardelmann E; Büttner R; Merkelbach-Bruse S
Oncotarget; 2015 Aug; 6(24):20215-30. PubMed ID: 26036639
[TBL] [Abstract][Full Text] [Related]
56. Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer.
Pitts TM; Bradshaw-Pierce EL; Bagby SM; Hyatt SL; Selby HM; Spreafico A; Tentler JJ; McPhillips K; Klauck PJ; Capasso A; Diamond JR; Davis SL; Tan AC; Arcaroli JJ; Purkey A; Messersmith WA; Ecsedy JA; Eckhardt SG
Oncotarget; 2016 Aug; 7(31):50290-50301. PubMed ID: 27385211
[TBL] [Abstract][Full Text] [Related]
57. Pre-clinical characterization of PKC412, a multi-kinase inhibitor, against colorectal cancer cells.
Li JP; Huang ZJ; Lu XS; Zhou YC; Shao Y; He XP; Chen SR; Wang DD; Qin LS; Sun WH
Oncotarget; 2016 Nov; 7(47):77815-77824. PubMed ID: 27780925
[TBL] [Abstract][Full Text] [Related]
58. Interaction between the estrogen receptor and fibroblast growth factor receptor pathways in non-small cell lung cancer.
Siegfried JM; Farooqui M; Rothenberger NJ; Dacic S; Stabile LP
Oncotarget; 2017 Apr; 8(15):24063-24076. PubMed ID: 28445992
[TBL] [Abstract][Full Text] [Related]
59. In vivo analysis of insulin-like growth factor type 1 receptor humanized monoclonal antibody MK-0646 and small molecule kinase inhibitor OSI-906 in colorectal cancer.
Leiphrakpam PD; Agarwal E; Mathiesen M; Haferbier KL; Brattain MG; Chowdhury S
Oncol Rep; 2014 Jan; 31(1):87-94. PubMed ID: 24173770
[TBL] [Abstract][Full Text] [Related]
60. Combination of EGFR/HER2 tyrosine kinase inhibition by BIBW 2992 and BIBW 2669 with irradiation in FaDu human squamous cell carcinoma.
Schütze C; Dörfler A; Eicheler W; Zips D; Hering S; Solca F; Baumann M; Krause M
Strahlenther Onkol; 2007 May; 183(5):256-64. PubMed ID: 17497097
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]